I recently had the pleasure of sitting down with Fabian Gerlinghaus, CEO of Cellares. They are working on closed-system full automation to manufacture cell therapies.
Onyx Studio Sessions: Fabian Gerlinghaus, CEO, Cellares
Can Cellares bring down the cost of some of the most expensive new therapies on the market?
Related
Chris Hall, CEO, Personalis | Onyx Live | JPM 2026
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
Adrian Gottschalk, CEO, Foghorn Therapeutics | Onyx Live | JPM 2026
The machinery that governs gene expression is being targeted to beat cancer.
Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
Daniel Green, CEO, eSpraye | JPM 2026
If the disease is in the lungs, why deliver the drugs everywhere else?